Search Results
Your search for ,NOW matches 6737 pages
Showing 4151 - 4200Moderate Activity May Improve Overall and Progression-Free Survival in Patients With Metastatic Colorectal Cancer
Patients with metastatic colon cancer who exercise may live longer, according to an analysis of the CALGB/SWOG 80405 trial presented at the 2017 Gastrointestinal Cancers Symposium.1 According to the authors, this is the first study to demonstrate an association between physical activity and...
Expert Point of View: Nancy Baxter, MD, PhD & Steven H. Lin, MD, PhD
“CALGB 80803 really helps move the field forward,” said press briefing moderator and ASCO spokesperson Nancy Baxter, MD, PhD, a surgeon from St. Michael’s Hospital in Toronto, Ontario, Canada. “PET [positron-emission tomography] scans may prove to be a valuable tool to help oncologists fine-tune...
Early PET Imaging May Guide Treatment Decisions in Esophageal Cancer
In patients with resectable esophageal or gastroesophageal junction cancer, positron-emission tomography (PET) imaging was used to assess response to induction chemotherapy. PET nonresponders were identified after the first few cycles and were switched to an alternate regimen. This strategy greatly ...
Expert Point of View: Milind Javle, MD
Milind Javle, MD, Professor of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, Houston, discussed the findings from the CheckMate 040 trial presented at the 2017 Gastrointestinal Cancers Symposium. There is a strong rationale for investigating immunotherapy in liver ...
Nivolumab Shows Benefit in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, treatment with nivolumab (Opdivo) resulted in responses and long-term survival in patients who were either previously treated or naive to sorafenib (Nexavar), CheckMate 040 has shown.1 Altogether 19% of patients responded to the antibody...
Progress Being Made in Understanding Immunotherapy Resistance
A key challenge in advancing immunotherapies is to understand mechanisms of response and resistance. Emerging research in this area—including evidence that early on-treatment biopsies can predict response—was discussed at the 2017 ASCO-SITC (Society for Immunotherapy of Cancer) Clinical...
Expert Point of View: Ann W. Silk, MD
Ann W. Silk, MD, of Rutgers Cancer Institute of New Jersey, New Brunswick, presented the day’s highlights and commented that the study by Hellmann et al shows the utility, and, in fact, the necessity, of developing a new means of estimating outcomes for patients treated with immunotherapies....
Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests
Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.1 “In...
Adding Temozolomide to Short-Course Radiotherapy in Older Patients With Glioblastoma
In a phase III trial reported in The New England Journal of Medicine, Perry et al found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged ≥ 65 years with newly diagnosed glioblastoma. The survival advantage was largest among patients with methylated ...
Douglas E. Wood, MD, on Lung Cancer Screening
Douglas E. Wood, MD, of the University of Washington, discusses the importance of broad access to and education about lung cancer screening—now approved for people at high risk for the disease—and the need for expanded criteria for screening eligibility.
Tracey L. Evans, MD, on NSCLC: Combined-Modality Therapy
Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunotherapy, and some of the controversies now debated.
ASCO Statement: President's Budget Will Devastate U.S. Research Enterprise
ASCO President Daniel F. Hayes, MD, FACP, FASCO, released the following statement today: “We soundly oppose President Trump's budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH's funding by nearly 20% will devastate our nation's...
SGO 2017: Hospital Readmission Metrics May Not Be an Ideal Measure in Ovarian Cancer Cases
To reduce costs and improve quality of care, the Centers for Medicare & Medicaid Services (CMS) has made reducing hospital readmission rates a priority, yet two research studies presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer question the use...
SGO 2017: New Immunotherapy Axalimogene Filoslisbac Shows Positive Results in Cervical Cancer
A new immunotherapy drug, axalimogene filoslisbac (AXAL), showed improved survival rates for patients with cervical cancer, according to a study presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Study coauthor Charles Leath, MD, MSPH, an SGO member ...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
Preclinical Study Finds SPOP Mutation Drives Prostate Cancer Subtype
A genetically engineered mouse model developed by Blattner et al investigating the role of the gene Speckle Type BTB/POZ Protein, or SPOP, as a driver of prostate cancer has found that the mutation drives prostate neoplasia through coordinate deregulation of both P13K/mTOR and androgen receptor...
ACC.17: History of Exercise Helps Prevent Heart Disease After Breast Cancer
Regular exercise appears to help mitigate the increased cardiovascular risk faced by women treated for breast cancer, according to a study scheduled for presentation at the American College of Cardiology's 66th Annual Scientific Session (ACC.17). The study found that women with breast cancer who...
UK Trial Shows No Survival Benefit in Adding Pravastatin to Standard Chemotherapy in Small Cell Lung Cancer
In the UK phase III LUNGSTAR study reported in the Journal of Clinical Oncology, Seckl et al found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer (SCLC). Numerous large prospective cohort and registry studies...
Low-Grade Gliomas: Understanding the New Treatment Paradigm
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed, as detailed in a recent review in the Journal of Oncology Practice.1 The...
Value-Based Approaches to the Rising Costs of Cancer Drugs
It’s no secret that cancer drug costs have skyrocketed out of control, with some treatments costing as much as $100,000 to $200,000 per year and even upward. This has put tremendous strain on the U.S. health-care system, while causing financial toxicity and bankruptcy for many patients. Peter B....
Novel Immunotherapy Added to Standard Care Did Not Meet Endpoint in Patients With Advanced Head and Neck Cancer
In the phase II Active8 trial, a novel immunotherapy agent, motolimod, failed to improve outcomes over chemotherapy plus cetuximab (Erbitux) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In a post hoc analysis, however, patients with injection-site...
Scientists Tackle Next Set of Immunotherapy Challenges
Cancer immunotherapy is about to get much more complicated. Just as oncologists are becoming familiar with checkpoint inhibitors and their growing indications, they will eventually be challenged with using them in novel combinations and in new tumor types. This will be the fruit that comes from...
Can Antiviral Therapy Prevent Liver Cancer in Patients With Chronic Hepatitis?
Chronic viral hepatitis is a major causative factor for hepatocellular carcinoma, but antiviral therapy might reduce the incidence of hepatocellular carcinoma by preventing or eliminating chronic hepatitis infections, according to Adrian M. Di Bisceglie, MD, Professor of Internal Medicine at Saint ...
Expect Questions About the Cervical Cancer Mortality Study
A widely reported study found that cervical cancer mortality was higher and the racial disparity between black and white women greater than previously reported.1 The study omitted from the mortality estimates those women who had undergone hysterectomies, usually involving removal of the cervix....
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
Cancer Has Aged Me
The news that I had breast cancer came at an especially difficult time in my life and was quite shocking to hear. My father had died of lung cancer just 1 month before my diagnosis, and I was still grieving his death when I suddenly had to confront my own mortality. In retrospect, the diagnosis...
Building a Multidisciplinary Model of Care for Cancer Survivors
Last year’s inaugural Cancer Survivorship Symposium stressed the importance of bringing together the fields of medical oncology and primary care to ensure a coordinated effort to help patients with cancer transition to long-term survivorship care. Building on that goal, the 2017 Cancer Survivorship ...
Cleveland Clinic Opens New Taussig Cancer Center
The new Cleveland Clinic Taussig Cancer Center began welcoming patients on March 6, 2017. The 377,000 square-foot facility houses all outpatient cancer treatment services in one location, with the center’s team of medical and radiation oncologists, surgeons, nurses, genetic counselors, social...
CAR T-Cell Therapy Emerging in Multiple Myeloma
For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven...
A Decade of Lessons Learned From EGFR-Targeted Therapy
To summarize the lessons learned from the development of epidermal growth factor receptor (EGFR)-targeted therapy, one only has to go back about 10 years, according to Frances A. Shepherd, MD, Scott Taylor Chair in Lung Cancer Research at Princess Margaret Cancer Centre and Professor of Medicine at ...
Expert Point of View: Susan F. Slovin, MD, PhD
Formal discussant for the presentation of SWOG S9921 results, Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, said there were some important points to understand about this “vintage” trial. “The trial was designed 20 years ago, and the view is...
No Benefit From Older Standard-of-Care Drug in Adjuvant Chemotherapy for High-Risk Prostate Cancer, but Newer Trials Feasible
An older trial designed to evaluate the benefits of adjuvant therapy following radical prostatectomy in patients with high-risk prostate cancer showed no difference in overall or disease-free survival between 2 years of androgen-deprivation therapy and 2 years of androgen-deprivation therapy plus...
Phase II Trial Evaluates New Gene Therapy for Non–Muscle Invasive Bladder Cancer After BCG
A novel approach using intravesical gene therapy showed promising activity in a phase II trial that enrolled patients with bacillus Calmette-Guérin (BCG)-refractory or -relapsed nonmuscle invasive bladder cancer.1 The rate of high-grade relapse-free survival at 12 months was 35% in patients treated ...
Make Vaccination Great Again
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. It affects 80% of individuals, with the initial infection usually occurring between the ages of 15 and 24. Persistent infection with oncogenic HPV genotypes, primarily 16 and 18, is the cause of virtually all...
Robert S. Miller, MD, on CancerLinQ: Big Data and Clinical Effectiveness
Robert S. Miller, MD, of ASCO, updates the progress of CancerLinQ and its data set, now being used by oncologists to track quality measurement and reporting.
Ethan M. Basch, MD, on Symptom Control and Quality: The Patient’s Voice
Ethan M. Basch, MD, of The University of North Carolina at Chapel Hill, discusses programs—now rolling out at various institutions—that use direct patient reporting of symptoms as a part of quality assessment (Posters 61, 81; Abstract 218).
Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, a research team from The University of Texas MD Anderson Cancer Center reported in a study by Balasenthil et al in the ...
Poor Diet During Adolescence/Early Adulthood and Risk for Premenopausal Breast Cancer
Although adolescence is a highly susceptible time for mammary carcinogenesis, few prospective studies have examined the role of adolescent diet and breast cancer risk. Now, a study investigating the association of an adolescent and early adulthood dietary pattern that promotes chronic inflammation...
ASCO Quality Care 2017: In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors
An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in...
Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers...
Remembering Stephen K. Carter, MD, and His National and International Impact on Early Drug Development
Stephen K. Carter, MD, a renowned oncologist who held a variety of executive positions in the pharmaceutical industry and played a major role in the research and development of many widely used cancer and AIDS drugs, died on November 14, 2016, after a long battle against multiple systems atrophy....
Cancer Has Made Me the Person I Am
My breast cancer diagnosis in 1993, at age 34, came at the happiest moment in my life. I had gotten married just 10 months earlier and was looking forward to the future and children. But instead of celebrating my first wedding anniversary with my husband over a romantic dinner, we were at a cancer ...
Expect Questions About Screening and Potential Overdiagnosis
“The big thing that is going to become more and more of an issue, and that you are going to hear a lot more of this year, and in the next several years, is overdiagnosis,” Otis W. Brawley, MD, FACP, Chief Medical Officer of the American Cancer Society, told The ASCO Post in an interview following...
Continued Reduction in Cancer Mortality Requires Increasing Healthy Behaviors and Removing Inequities in Care
Many news reports about the latest cancer statistics released by the American Cancer Society (ACS) have focused on the 25% reduction in cancer mortality since 1991. Several reports quoted ACS Chief Medical Officer Otis W. Brawley, MD, FACP, who said in a statement1 announcing the publication of...
Soy
Scientific Name: Glycine max Common Names: Soybean, soya, tofu, miso, tempeh Overview An annual herb indigenous to East Asia, soy was domesticated more than 3,000 years ago for its pods and edible seeds. It is now the world’s most important legume crop and is grown in diverse climates. Foods...
Regorafenib in Second-Line Setting for Hepatocellular Carcinoma: Balancing Benefit With Toxicity
During the past 40 years, hundreds of randomized trials testing treatments for advanced hepatocellular carcinoma have been published.1 Conventional systemic chemotherapy and radiotherapy lack survival advantages for these patients.1,2 In 2007, a phase III trial demonstrated survival benefits for...
Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer
The AURA3 study—reported by Mok and colleagues and reviewed in this issue of The ASCO Post—confirms the dramatic activity of osimertinib (Tagrisso) in patients with advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and acquired resistance to prior EGFR...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bangladesh
The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the convenience of the reader, each issue will focus on one country from one of the six regions...
Radiotherapy vs Temozolomide in Low-Grade Glioma: The Importance of Molecular Classification
The optimal treatment strategy for low-grade glioma has yet to be established, and practice patterns vary in regard to the timing of treatment, as well as the chosen treatment modality. It was against this backdrop, at a time when the benefits of radiation and chemotherapy remained uncertain but ...
